预约演示

更新于：2025-05-07

Pulmonary Arteriovenous Fistulas

肺动静脉瘘

更新于：2025-05-07

基本信息

别名

Arteriovenous fistula of pulmonary vessels、Arteriovenous fistula of pulmonary vessels (disorder)、FISTULA, ARTERIOVENOUS, PULMONARY

+ [19]

简介

A congenital or acquired malformation characterized by abnormal communication between the pulmonary arteries and pulmonary veins in the lungs.

关联

项与肺动静脉瘘相关的临床试验

NCT06735976

/ RecruitingN/AIIT

Efficacy & Safety of LOBO™ Vascular Occlusion Device for Embolization of Pulmonary Arteriovenous Malformations (PAVM)

The goal of this clinical trial is to evaluate both the technical success and efficacy of using the LOBO™ device in patients undergoing embolization of Pulmonary Arteriovenous Malformations (PAVM). The main question[s] it aims to answer [is/are]:
* What is the technical success rate, the number of LOBO™ devices needed for occlusion, and time to occlusion for each feeding artery during PAVM embolization using the LOBO™ device?
* What is the short-term occlusion rate of the LOBO™ device for PAVM embolization (6 months post-embolization)?
* What are the medium- and long-term occlusion rate of the LOBO™ device in PAVMs (12 months and 36 months post embolization)?
Researchers will compare the percentage of LOBO™ embolized PAVMs that develop recanalization at 6, 12, and 36- month intervals compared to percentage of conventionally embolized PAVMs that develop recanalization at the same intervals.
Participants will undergo the embolization procedure and be followed for 36 months after the procedure. There will be a total of 4 study visits:
* Treatment visit
* 6-Month Follow-up visit
* 12-Month Follow-up visit
* 36-Month Follow-up visit
At each clinical follow-up visit participants will undergo imaging with a computed tomography angiography (CTA) of the chest.

开始日期2024-12-17

申办/合作机构

The University of North Carolina at Chapel Hill

[+1]

ChiCTR2400086665

/ Suspended早期临床1期IIT

Effect of esketamine on pulmonary shunt in patients undergoing thoracoscopic pulmonary resection

开始日期2024-07-30

申办/合作机构

重庆医科大学附属第二医院

NCT06099015

/ RecruitingN/A

Cera™ Vascular Plug System Post-Market Clinical Follow-Up: A Multi-center, Prospective, Observational, Single-arm, Open-label, Post-market Study

The objective of the study is to collect and evaluate clinical data on patients of the Lifetech Cera™ Vascular Plug System to:
* confirm the performance
* confirm the safety
* identify previously unknown side-effects
* monitor the identified side-effects (related to the procedures or to the medical devices)
* identify and analyse emergent risks

开始日期2024-06-21

申办/合作机构

先健科技公司

100 项与肺动静脉瘘相关的临床结果

登录后查看更多信息

100 项与肺动静脉瘘相关的转化医学

登录后查看更多信息

0 项与肺动静脉瘘相关的专利（医药）

登录后查看更多信息

2,686

项与肺动静脉瘘相关的文献（医药）

2025-06-01·Radiology Case Reports

Successful coil embolization of 3 pulmonary arteriovenous malformations using a gadolinium contrast agent in a patient with severe iodine allergy: A case report

Article

作者: Kamisako, Atsufumi ; Murotani, Kazuhiro ; Naka, Takahiro ; Ikoma, Akira ; Tamai, Kurumi ; Minamiguchi, Hiroki ; Mimura, Ryosuke ; Sonomura, Tetsuo ; Miyake, Yuichi

We report the first successful coil embolization using a gadolinium contrast agent (GCA) of 3 pulmonary arteriovenous malformations (PAVMs) in a patient with severe iodine allergy. The patient was a female in her 40s with hereditary hemorrhagic telangiectasia. The 3 PAVMs had sacs with diameters of up to 20 mm and pulmonary feeding arteries with diameters of up to 5 mm. The PAVMs were located in segment (S) 8 and S9 of the right lung, and S8 of the left lung. Embolization was planned after administration of steroids and antihistamines. However, the procedure was stopped because preoperative pulmonary arteriography using an iodine contrast agent caused pharyngeal itching, coughing, and decreased percutaneous oxygen saturation. Because surgical resection is highly invasive, embolization using a GCA was selected as an alternative treatment strategy. After obtaining approval from our hospital's ethical review board, embolization with a GCA was planned. Embolization was performed in 3 separate sessions. The catheter's position was monitored and adjusted under angiography with manual injection of a GCA and low-dose computed tomography (CT) using an interventional radiology-CT system. The GCA was visible on angiography and coil embolization of the PAVM sacs and feeding arteries was performed. A small amount of GCA was used (7‒9 mL). The patient experienced no allergic reactions during the procedure. Although there are many reports of endovascular treatment using GCA for dialysis shunt stenosis and cerebrovascular disease in patients with iodine allergy, this is the first report describing the use of GCA during PAVM embolization.

2025-05-01·Radiology Case Reports

Differentiating systemic artery-to-pulmonary artery fistula from pulmonary arteriovenous malformation: A case report

Article

作者: Asayama, Yoshiki ; Kawaguchi, Hiroyuki ; Baba, Hiroshi ; Hidaka, Hiromu ; Fukasawa, Kazunori

This report describes a rare case of a systemic artery-to-pulmonary artery fistula initially misdiagnosed as a pulmonary arteriovenous malformation in a 64-year-old male with severe emphysema. While a suspected pulmonary arteriovenous malformation was identified in the left lung on plain computed tomography, contrast-enhanced imaging revealed an aneurysmal nodule connected to the left inferior phrenic and internal mammary arteries, suggesting a systemic artery-to-pulmonary artery fistula. Selective angiography confirmed the diagnosis. The absence of pulmonary vein dilation on computed tomography is the key to differentiating a systemic artery-to-pulmonary artery fistula from a pulmonary arteriovenous malformation. Additionally, using contrast-enhanced computed tomography with both pulmonary artery and late phases helps prevent misdiagnosis of pulmonary embolism and may raise the suspicion of a systemic artery-to-pulmonary artery fistula.

2025-05-01·Journal of Vascular and Interventional Radiology

Embolotherapy for Pulmonary Arteriovenous Malformations in the Pediatric Population with Hereditary Hemorrhagic Telangiectasias—A Retrospective Case Series

Article

作者: Misra, Sanjay ; Iyer, Vivek ; Mukhtar, Haseeb ; Bjarnason, Haraldur ; Bendel, Emily C ; Demirel, Nadir

PURPOSETo investigate the outcomes of embolotherapy for pulmonary arteriovenous malformation (pAVM) management and investigate factors associated with pAVM persistence after embolotherapy in pediatric patients with hereditary hemorrhagic telangiectasia (HHT).MATERIALS AND METHODSPediatric patients with HHT who received embolotherapy for pAVMs at the institute were retrospectively identified from January 1, 1999, to January 31, 2024. Cases with adequate clinical and imaging follow-up and without prior pAVM treatment at another institution were included. Demographic, clinical, and procedural data were obtained from the electronic health record. Univariate Cox proportional hazard models were used to determine factors associated with primary pAVM persistence (re-establishment of an arteriovenous connection in a pAVM after the first embolotherapy).RESULTSTwenty-one patients (median age, 15 years; range, 3-19 years) underwent embolotherapy for 65 different pAVMs (median follow-up time, 7.56 years; range, 0.13-24.4 years). In total, 3 procedural adverse events occurred, including 1 severe event of a coil migration to the cerebral circulation. Primary persistence occurred in 23.1% of the treated pAVMs, with recanalization only being the most common cause of (73.3%), followed by untreated feeding vessels (20.0%) and recanalization along with formation of new collaterals to the pAVM (6.7%). Age less than the median cutoff of 15 years (P = .044) and greater maximum diameter of the plugs/coils (P = .011) were significantly associated with primary persistence on univariate analysis.CONCLUSIONSEmbolotherapy of pAVMs in pediatric patients with HHT was safe, with a high rate of persistence when coils were predominantly used. The risk of primary persistence was associated with age less than 15 years and the use of larger diameter plugs/coils.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

Eureka LS:

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。